The European Commission is planning to publish draft legislation later this year that will offer a way of avoiding post-Brexit regulatory and drug supply challenges that many pharmaceutical companies are facing when it comes to marketing products in Northern Ireland.
The thrust of the proposal is to allow certain regulatory compliance procedures such as batch release to be permanently carried out in Great Britain for products that are destined solely for the Northern Ireland (NI) market, rather than requiring
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?